Nexstim Oyj: Nexstim Plc Announces Resolutions of the Shareholder s Nomination Board
Nexstim Plc Announces Resolutions of the Shareholder s Nomination Board
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces resolutions of its Shareholder s Nomination Board.
Rohan Hoare, who has been a member of Nexstim s Board of Directors since 2016, and Tomas Holmberg, who has been a member of Nexstim s Board of Directors since 2017, have announced that they will no longer be available to the company s Board of Directors for the period 2021-2022. At its meeting, the Nomination Board of the Company has decided to propose to the General Meeting Timo Hildén and Tero Weckroth as new members of the Board.
Standard Insurance Company (The Standard) has promoted Harrison Weaver to second vice president and actuary, Corporate Actuarial and Risk Management. In his
LONDON, Jan. 20, 2021 /PRNewswire/ This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Share this article
STOCKHOLM, Jan. 15, 2021 /PRNewswire/
Cyxone (publ.) announced today that the first patient has been screened in the Phase 2 clinical trial of Rabeximod in Covid-19. The trial will evaluate the efficacy and safety of oral treatment with Rabeximod to prevent disease progression in hospitalized Covid-19 patients and shorten the time to recovery. The study will include 300 patients at clinical centers in Poland, Slovakia and up to three additional countries in Europe. Cyxone expects to announce preliminary results in the third quarter of 2021.
Cyxone recently announced that the company had received regulatory approval to initiate a double-blind placebo-controlled Phase 2 clinical trial of Rabeximod in Poland, where the first site was opened in December 2020. The company has also filed for regulatory approval in Slovakia, Hungary and Ukraine, and is preparing for submissions in additional countries. Rabeximod is being evaluated in patients suffering from moderat